Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure?

Blood

Volumn 99, Issue 3, 2002, Pages 768-784

  Burt, Richard K ^a,b,c,d   Slavin, Shimon ^a,b,c,d   Burns, William H ^a,b,c,d   Marmont, Alberto M ^a,b,c,d  

^a NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GLATIRAMER; INTERFERON BETA SERINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELPHALAN; THYMOCYTE ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOTRANSPLANTATION; DISEASE ACTIVITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MORTALITY; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; REMISSION; REVIEW; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; WHOLE BODY RADIATION;

EID: 0036464664     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.768     Document Type: Review

References (358)

1. Defining criteria for autoimmune diseases
2. Defining criteria for autoimmune diseases
3. Demonstration of a thrombocytopenic factor in the blood of patients with thriombocytopenic purpura
4. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn
5. Antiacetylcholine receptor antibody in neonatal myasthenia gravis
6. Passive immune thrombocytopenia in neonates of mothers with idiopathic thrombocytopenic purpura: Incidence and risk factors
7. Fetal thrombocytopenia and its relation to maternal thrombocytopenia
8. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: Further evidence for adoptive autoimmunity
9. Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma
10. Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease
11. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation
12. Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant
13. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia
14. Discrimination and dialogue in the immune system
15. A modification of Jerne's theory of antibody production using the concept of clonal selection
16. A clonal deletion model for Ir gene control of the immune response
17. The role of the T cell receptor in positive and negative selection of developing T cells
18. Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus
19. Tolerance: A case of self/not-self discrimination maintained by clonal deletion?
20. Thymic requirement for clonal deletion during T cell development
21. T cell tolerance by clonal elimination in the thymus
22. Clonal deletion versus clonal anergy: The role of the thymus in inducing self tolerance
23. A cell culture model for T lymphocyte clonal anergy
24. The role of clonal anergy in the avoidance of autoimmunity: Inactivation of autocrine growth without loss of effector function
25. A nondeletional mechanism of thymic self tolerance
26. Selecting the T cell receptor repertoire
27. A differentialavidity model for T-cell selection
28. Positive and negative thymocyte selection induced by different concentrations of a single peptide
29. Peripheral T cell tolerance
30. Contemporary models for peripheral tolerance and the classical "historical postulate."
31. A theory of self-nonself discrimination
32. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation
33. B70 antigen is a second ligand for CTLA-4 and CD28
34. The B7 and CD28 receptor families
35. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28
36. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
37. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway
38. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
39. A novel receptor involved in T-cell activation
40. Differential T cell costimulatory requirements in CD28-deficient mice
41. The role of CD40 ligand in costimulation and T-cell activation
42. The CD40 antigen and its ligand
43. Requirement for CD40 ligand costimulation induction, T cell activation, and experimental allergic encephalomyelitis
44. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity
45. Immunologic "ignorance" of vascularized organ transplants in the absence of secondary lymphoid tissue
46. Peripheral clonal elimination of functional T cells
47. Death by neglect as a deletional mechanism of peripheral tolerance
48. Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance
49. Suppressor T cells: Rebirth, function and homeostasis
50. Regulatory T cells in autoimmmunity
51. The role of different subsets of T regulatory cells in controlling autoimmunity
52. Persistence of physiological self antigen is required for the regulation of self tolerance
53. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
54. Tolerance, danger, and the extended family
55. 50 Million years of chordate evolution: Seeking the origins of adaptive immunity
56. Innate immunity
57. The instructive role of innate immunity in the acquired immune response
58. Innate immunity: Impact on the adaptive immune response
59. Integrating innate and adaptive immunity in the whole animal
60. Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus
61. Self-tolerance: Context dependent tuning of T cell antigen recognition
62. Adaptive cellular interactions in the immune system: The tunable activation threshold and the significance of subthreshold responses
63. Current trends in drug-induced autoimmunity
64. The role of infection in the pathogenesis of autoimmune disease
65. Viral damage and the breakdown of self-tolerance
66. Disruption of positive selection of thymocytes causes autoimmunity
67. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus
68. Etiology and mechanisms of drug-induced lupus
69. Effects of cyclosporine A on T cell development and clonal deletion
70. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease
71. Defective de novo thymocyte maturation in cyclosporin A (CsA)-induced autoimmunity: Expression of costimulatory and activation molecules
72. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity
73. Assessment of thymic output in adults after haematopoletic stem-cell transplantation and prediction of T-cell reconstitution
74. Evidence for thymic function in the elderly
75. Changes in thymic function with age and during the treatment of HIV infection
76. Autoimmune diabetes. Retrovirus as trigger, precipitator or marker?
77. Coxsackie B viruses and autoimmune diabetes
78. Coxsackie viruses and diabetes
79. Coxsackie viruses and diabetes
80. HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?
81. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis
82. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis
83. Extended observations on the association of HHV-6 and multiple sclerosis
84. The association between multiple sclerosis and infection with Epstein-Barr virus and retrovirus
85. Viruses and multiple sclerosis
86. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients
87. Coxsackie virus myocarditis
88. Review of microbial infections and the immune response to cardiac antigens
89. Dilated cardiomyopathy and enteroviruses
90. Mycobacteria and rheumatoid arthritis
91. Mycoplasmas and arthritis
92. Rheumatoid arthritis-an infectious disease?
93. Evidence that Chlamydia trachomatis causes seronegative arthritis in women
94. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis
95. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis
96. Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis
97. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus
98. Molecular mimicry and autoimmunity
99. Autoimmunity. The pathogen connection
100. The functional significance of epitope spreading and its regulation by co-stimulatory molecules
101. Epitope spreading: The role of self peptides and autoantigen processing by B lymphocytes
102. Bystander activation of cytotoxic T cells: Studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model
103. Vaccination and autoimmunity-"vaccinosis": A dangerous liaison?
104. Immunologic aspects of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease
105. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
106. Do superantigens play a role in autoimmunity?
107. Modulation of disease by superantigens
108. Superantigens-powerful modifiers of the immune system
109. Superantigens: Mechanisms by which they may induce, exacerbate and control autoimmune diseases
110. The structural basis of T cell activation by superantigens
111. Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system
112. The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders
113. Epitope spreading
114. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis
115. Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: Evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes
116. Epitope spreading in experimental autoimmune myasthenia gravis
117. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: Epitope spreading versus clonal persistence
118. Analysis of epitope spreading over an eleven-year period in a patient with systemic lupus erythematosus
119. Epitope spreading in paraneoplastic pemphigus: Autoimmune induction in antibodymediated blistering skin diseases
120. + epitope spreading and differential T cell recognition of muscle acetylcholine receptor subunits in myasthenia gravis
121. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes
122. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes
123. Evidence for epitope spreading and active suppression in skin graft tolerance after donor-specific transfusion
124. Persistent allopeptide reactivity and epitope spreading in chronic rejection
125. Persistent allopeptice reactivity and epitope spreading in chronic rejection of organ allografts
126. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system
127. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1996. Cellular immune recognition and the biological role of major transplantation antigens
128. MHC class-II molecules and autoimmunity
129. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibiity to rheumatoid arthritis
130. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region
131. HLA rheumatoid arthritis
132. Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: The disease is associated with a common determinant of the various B27 molecules
133. HLA autoimmunity in scleroderma (systemic sclerosis)
134. Polygenic control of autoimmune diabetes in nonobese diabetic mice
135. New Zealand mixed mice: A genetic systemic lupus erythematosus model for assessing environmental effects
136. Genetic dissection of systemic lupus erythematosus
137. Animal models of rheumatoid arthritis
138. Collagen-induced arthritis, an animal model of autoimmunity
139. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats
140. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis
141. Twin studies in medicine-what do they tell us?
142. Stem cell transplantation in experimental models of autoimmune disease
143. Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation
144. Effective treatment of mice with type II collagen induced arthritis with lethal irradiation and bone marrow transplantation
145. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis
146. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation
147. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation
148. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation
149. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT
150. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis
151. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation
152. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis
153. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation
154. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation
155. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease
156. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma
157. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation
158. + cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: Complete remission of lymphoma with control of autoimmune complications
159. Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation
160. Autologous PBPCT in a patient with lymphoma and Sjogren's syndrome: Complete remission of lymphoma without control of the autoimmune disease
161. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy
162. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation Blood
163. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: Prolonged complete remission after unmanipulated PBPC autotransplant
164. Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: Regression of both diseases after autologous bone marrow transplantation
165. Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia
166. Collection of hematopoietic stem cells from patients with autoimmune diseases
167. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor
168. Treatment of severe multiple sclerosis (MS) with high dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)
169. Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome: A cautionary case report
170. Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: Experimental background and rationale for ABMT
171. Immunablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease
172. Autologous bone-marrow transplantation for rheumatoid arthritis
173. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis
174. High-dose chemotherapy and syngeneic hemopoietic stemcell transplantation for severe, seronegative rheumatoid arthritis
175. Treatment of systemic sclerosis with autologous haemopoietic stem cell
176. Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura
177. Autologous blood stem cell transplantation can overcome and modulate therapeutic resistance in severe rheumatoid arthritis [abstract]
178. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
179. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: Sustained response in two of four patients
180. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study
181. Haematopoietic stem cell transplantation for active systemic lupus erythematosus
182. Hematopoietic stem-cell transplantation for systemic lupus erythematosus
183. +) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome
184. +) cell transplantation
185. Haemopoietic stem-cell transplantation for juvenile chronic arthritis
186. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis
187. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells
188. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis
189. Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
190. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study
191. + purified autologous stem cells from peripheral blood
192. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients
193. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis
194. + selected peripheral blood stem cell (PBSC) rescue as treatment for severe systemic sclerosis
195. Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis
196. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: Report of toxicity and immunological monitoring
197. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation
198. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration
199. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura
200. The effect of various cytotoxic agents on bone marrow progenitor cells as measured by diffusion chamber assays
201. Myeloproliferative disorders in patients with rheumatoid arthritis treated with total body irradiation
202. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis
203. Solid cancers after bone marrow transplantation
204. Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality
205. Update: Center effects
206. Vaccinations and the risk of relapse in multiple sclerosis
207. Multiple sclerosis
208. The natural history of multiple sclerosis: Update 1998
209. The natural history of multiple sclerosis
210. Natural history of multiple sclerosis
211. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
212. Interferon (beta)-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
213. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis
214. Placebo-controlled multicentre randomised trial of interferon (beta)-1b in treatment of secondary progressive multiple sclerosis
215. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
216. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebocontrolled trial
217. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
218. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
219. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
220. Cause of death in patients attending multiple sclerosis clinics
221. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies
222. Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment
223. Relapses and progression of disability in multiple sclerosis
224. Axonal transection in the lesions of multiple sclerosis
225. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study
226. Imaging axonal damage of normal-appearing white matter in multiple sclerosis
227. Axonal damage in acute multiple sclerosis lesions
228. Bone marrow transplantation for multiple sclerosis
229. Immune suppressive therapy with autologous hematopoietic stem cell transplantation arrests active CNS inflammation but not axonal atrophy in patients with severe disability and progressive multiple sclerosis
230. Autologous hempatopoietic stem cell transplantation suppresses gd-enhanced MRI activity in MS
231. +/HSCT) for multiple sclerosis: Update of a single center experience in 10 patients
232. Bone marrow transplantation in multiple sclerosis
233. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
234. Genetic susceptibility to spontaneous lupus in mice
235. An outsider's view on SLE research
236. Epidemiology of systemic lupus erythematosus
237. Etiopathogenesis of systemic lupus erythematosus: A tale of three troikas
238. Systemic lupus erythematosus
239. Old treatmentnew treatment
240. Cyclophosphamide for the treatment of systemic lupus erythematosus
241. Treatment-resistant rheumatic disease
242. Perspective: Immunoablation with stem cell rescue: A possible cure for systemic lupus erythematosus
243. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell infusion for severe autoimmune diseases
244. Eminence-based medicine. Lupus: Tinkering with hematopoietic stem cells
245. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus
246. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE
247. Measurement of systemic lupus erythematosus activity in clinical research
248. Serial assessment of glomerular filtration rate in lupus nephropathy
249. Crosscultural validation and reliability of three disease activity indices in systemic lupus erythematosus
250. Sensitivity to change of three SLE disease activity indices: International validation
251. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis
252. Etiology and pathogenesis of rheumatoid arthritis
253. T cell receptor repertoire in rheumatoid arthritis
254. TCR beta spectratyping in RA: Evidence of clonal expansions in peripheral blood lymphocytes
255. T cell recognition of stress proteins. A link between infectious and autoimmune disease
256. Accumulation of T cells reactive to type II collagen in synovial fluid of patients with rheumatoid arthritis
257. Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: Quantitative and functional aspects
258. Anchorage-independent growth of synoviocytes from arthritic and normal joints: Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids
259. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice
260. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts
261. Non-articular complications of rheumatoid arthritis
262. Rheumatoid arthritis: Extra-articular manifestations. II
263. Mortality in the rheumatic diseases
264. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures
265. Survival, prognosis, and causes of death in rheumatoid arthritis
266. Mortality predictors among 263 patients with rheumatoid arthritis
267. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis
268. Length of life and cause of death in rheumatoid arthritis
269. Mortality in rheumatoid arthritis
270. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis
271. Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup
272. Survivorship and death in rheumatoid arthritis
273. Biologic therapy for rheumatoid arthritis
274. High dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy
275. T-cell-depleted stem-cell transplantation for rheumatoid
276. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
277. Epidemiology, demographics, genetics
278. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit
279. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis
280. Predictors of survival in systemic sclerosis (scleroderma)
281. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)
282. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population
283. Mortality in systemic sclerosis: A comparison with the general population
284. Major histocompatibility complex class II genes and systemic sclerosis
285. Familial scleroderma: HLA antigens and autoantibodies
286. Highdose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
287. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial
288. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial
289. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
290. Vascular disease in progressive systemic sclerosis (scleroderma)
291. The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy)
292. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon
293. The Tight skin mouse: Demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils
294. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation
295. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse
296. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I
297. Topoisomerase I identified by scleroderma 70 antisera: Enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase
298. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis
299. Scleroderma-like changes due to chronic graft-versus-host disease
300. Graft-versus-host disease and animal models for scleroderma
301. In vivo demonstration of microvascular pathology by intravital microscopy in experimental chronic graft-versus-host disease: Analogy with scleroderma
302. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma
303. Microchimerism of maternal origin persists into adult life
304. Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation
305. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
306. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes
307. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT)
308. Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation
309. Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation
310. Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells
311. Prevention of coronary vascular disease by transplantation of T-cell-depleted bone marrow and hematopoietic stem cell preparation in autoimmune-prone w/BF(1) mice
312. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice
313. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice
314. Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice
315. Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue
316. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation
317. Rationale for bone marrow transplantation in the treatment of autoimmune diseases
318. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation
319. Transfer of tolerance
320. Hematopoietic cell transplantation for the induction of allo- and xenotolerance
321. Successful liver allografts in mice by combination with allogeneic bone marrow transplantation
322. Tolerance of allogeneic heart grafts in mice simultaneously reconstituted with purified allogeneic hematopoietic stem cells
323. Mixed hematopoietic chimerism prevents allograft vasculopathy
324. Cellular basis of long-term organ transplant acceptance: Pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance
325. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow
326. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
327. Hematopoietic stem cell therapy of autoimmune diseases
328. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
329. Graftversus-leukemia reactions after bone marrow transplantation
330. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in non-obese diabetic (NOD) mice
331. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice
332. Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation
333. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity
334. Non-myeloblative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice
335. Prevention and treatment of graft vs host disease by down regulation of antihost reactivity with veto cells of host origin
336. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia
337. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy
338. Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation
339. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: Late complications of therapy
340. Longterm outcome of autoimmune disease following allogeneic bone marrow transplantation
341. Bone marrow transplantation in patients with gold-induced marrow aplasia
342. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia
343. Clearance of severe psoriasis after allogeneic bone marrow transplantation
344. Resolution of immune mediated diseases following allogeneic bone marrow transplantation for leukaemia
345. Apparent cure of rheumatoid arthritis following bone marrow transplantation
346. Progression of rheumatoid arthritis following bone marrow transplantation: A case report with a 13-year followup
347. Resolution of autoimmune hepatitis after bone marrow transplantation
348. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin
349. Course of Crohn's disease after allogeneic marrow transplantation
350. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation
351. Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft
352. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation
353. Treatment of severe Evans syndrome with an allogeneic cord blood transplant
354. Allogeneic stem cell transplantation for Evans syndrome
355. Epstein-Barr virus (EBV)-associated post-transplant lympho-proliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases